JAMA Neurology

• JAMA Neurology

  Mission Statement: The mission of JAMA Neurology is to publish and disseminate scientific information primarily important for physicians caring for people with neurologic disorders and for those interested in the structure and function of the normal and diseased human nervous system. The specific aims are to (1) publish timely original research, including clinical trials that will directly improve clinical neurologic care and that will inform efforts to improve neurological health and promote health care equity; (2) report translational research that is pertinent to the understanding of neurologic disease; (3) address topics of practice, ethics, education, and public health that are a key part of modern medicine; and (4) provide a forum for discussion and publication of important topics including bias, racism, and diversity. This information will be published only after extensive review by scientific peers and journal editors so that clarity, rigor, originality, and precision are ensured.

• Education and Accelerated Tau Accumulation in Alzheimer Disease

  This cohort study investigates if higher educational attainment is associated with rate of tau accumulation.

• Error in Figure

  The Original Investigation titled “Fremanezumab for the Treatment of Patients With Migraine and Comorbid Major Depressive Disorder: The UNITE Randomized Clinical Trial,” published on May 5, 2025, was corrected to fix the misaligned data points in Figure 3C. This article was corrected online.

• Ambroxol as a Treatment for Parkinson Disease Dementia

  This randomized clinical trial investigates the safety and tolerability of ambroxol for Parkinson disease dementia (PDD) and its role as a potential disease-modifying treatment for PDD.

• Amyloid-Beta Pathology and Cognitive Performance in Centenarians

  This study explores whether amyloid beta pathology in centenarians is associated with cognitive performance.

• APOE and Intracranial Hemorrhage in Atrial Fibrillation

  This cohort study uses genetic association data from All of Us participants with atrial fibrillation who are treated with apixaban to determine whether being a carrier of the APOE ε4 allele increases the risk of intracranial hemorrhage.

• Meningitis as an Attack Phenotype of MOGAD-Associated Disease

  This international multicenter study seeks to determine the frequency and characteristics of meningitis in myelin oligodendrocyte glycoprotein antibody (MOGAD)–associated disease and highlight its pathology.

• Maternal SDOH and Risk of Perinatal Hypoxic-Ischemic Encephalopathy

  This cross-sectional study examines whether there are maternal social determinants of health associated with a risk of perinatal hypoxic-ischemic encephalopathy in neonates.

• A New Dystonia Phenotype in Wilson Disease

  This case report describes a 36-year-old male patient with Wilson disease and opposite muscle tone manifestations in his upper and lower limbs.

• Regional Differences in Dementia Incidence Among US Veterans

  This observational study investigates geographic differences in dementia incidence across the US among older adults in the Veterans Health Administration (VHA) system.

• White Matter Abnormalities and Cognition in Aging and Alzheimer Disease

  This prognostic study investigates the associations between tract-specific white matter microstructure and cognitive performance and decline in aging- and Alzheimer disease–related cognitive impairment.

• Spontaneous Intracranial Hypotension Due to Cerebrospinal Fluid Rhinorrhea

  This case report describes an 8-year-old girl who presented with cerebrospinal fluid rhinorrhea, brain sagging, and orthostatic headaches.

• Somebody to Love

  This essay describes a physician’s inspiration for a renewed sense of love in caring for patients.

• Global Burden of Subarachnoid Hemorrhage

  This cross-sectional study investigates the global burden of nontraumatic subarachnoid hemorrhage in 2021.

• Evaluations of the New Brunswick Neurological Syndrome of Unknown Cause

  This cross-sectional study examines findings from second, independent clinical evaluations of patients initially diagnosed with an alleged “mystery” neurological illness in New Brunswick, Canada, to determine whether there is evidence of such a disease.

• The Regulatory Landscape for Clinical Metagenomic Testing

  This Viewpoint discusses regulatory shifts and their effects on access to innovative diagnostic tests and provides ways to address regulatory barriers for clinical metagenomic testing.

• The Neurologist’s Imperative in Brain Death

  This Viewpoint discusses the importance of the diagnosis of brain death/death by neurologic criteria and provides context and history of the diagnosis.